scholarly journals Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study

2021 ◽  
Vol 10 (16) ◽  
pp. 3465
Author(s):  
Monica Casiraghi ◽  
Francesco Petrella ◽  
Giulia Sedda ◽  
Antonio Mazzella ◽  
Juliana Guarize ◽  
...  
Keyword(s):  
Lymph Node ◽  
Minimally Invasive ◽  
Open Surgery ◽  
Case Control Study ◽  
Locally Advanced ◽  
Case Control ◽  
Induction Treatment ◽  
Stage Iiia ◽  
Robot Assisted ◽  
Control Study

Despite there already being many studies on robotic surgery as a minimally invasive approach for non-small-cell lung cancer (NSCLC) patients, the use of this technique for stage III disease is still poorly described. These are the preliminary results of our prospective study on the safety and effectiveness of robotic approaches in patients with locally advanced NSCLC in terms of postoperative complications and oncological outcomes. Since 2016, we prospectively investigated 19 consecutive patients with NSCLC stage IIIA-pN2 (diagnosed by EBUS-TBNA) who underwent lobectomy and radical lymph node dissection with robotic approaches after induction treatment. Furthermore, we matched a case-control study with 46 patients treated with open surgery during the same period of time, with similar age, comorbidities, clinical stage and tumor size. The individual matched population was composed of 16 robot-assisted thoracic surgeries and 16 patients who underwent open surgery. The median time range of resection was inferior in the open group compared to robotic lobectomy (243 vs. 161 min; p < 0.001). Lymph node resection and positivity were not significantly different (p = 0.96 and p = 0.57, respectively). Moreover, no difference was observed for PFS (p = 0.16) or OS (p = 0.41). In conclusion, we demonstrated that the early outcomes and oncological results of N2-patients after robotic lobectomy were similar to those who had open surgery. Considering the advantages of minimally invasive surgery, robot-assisted lobectomy appears to be a safe approach to patients with locally advanced diseases.

Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10531-10531
Author(s):  
Anosheh Afghahi ◽  
Sydney Marsh ◽  
Alyse Winchester ◽  
Dexiang Gao ◽  
Hannah Parris ◽  
...  
Keyword(s):  
Lymph Node ◽  
Genetic Testing ◽  
High Risk ◽  
Case Control Study ◽  
Case Control ◽  
Low Risk ◽  
Mutation Status ◽  
T Stage ◽  
Chek2 Mutation ◽  
Control Study

10531 Background: Genomic assays, such as RS, are used to determine chemotherapy benefit in early-stage, estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2 negative BC patients (pts). Currently, guidelines to use pts’ germline genetic testing results to guide adjuvant therapy are lacking. Several reports have indicated worse outcomes for BC pts with g CHEK2 pathogenic variants (PV). We investigated whether PV in CHEK2 were associated with increased RS. Methods: Patient-level clinical data and RS were derived from electronic medical records of seven medical centers between years 2013-17. Confirmation of RS using the Genomic Health provider portal was performed. 38 pts with germline PV in CHEK2 (15 pts/39.5% with c.1100delC mutation) and RS score (cases) were matched with BC pts whose genetic testing did not identify PV (controls) using a 1:2 matching schema. Pts were matched based on age at diagnosis and lymph node (LN) status. LN negative pts were further matched based on T-stage. A multivariate random intercept linear mixed model of CHEK2 mutation status on RS was performed, adjusting for PR. A secondary ordinal univariate analysis was conducted that categorized RS into low, intermediate and high risk ( < 18, 18-30, and > 30, respectively). P-values were reported based on a null hypothesis of no effect against a two-sided alternative. Results: The median RS for cases was 19.5 (interquartile range [IQR]: 15 to 25) and the median RS for controls was 18 (IQR: 12 to 22). A greater proportion of cases were categorized as high risk (10.5%) compared to controls (5.6%), and a smaller proportion of cases were categorized as low risk (36.8%) compared to controls (49.3%). Cases had higher grade and increased proportion of PR-negative BC as compared with controls (grade 1: 12.1% of cases versus 32.4% of controls; PR-negative: 7.9% of cases versus 5.6% of controls). The variables used to match cases and controls (age, lymph node status, and T-stage) had similar summary statistics. The RS was 1.97-point higher in pts with g CHEK2 PV compared to controls, after adjusting for PR (95% confidence interval [CI]: 1.02-point lower to 4.96-point higher; p = 0.194). The secondary analysis of CHEK2 mutation status on an ordinal RS risk group yielded comparable results; on average, the odds of being high risk compared to the combined intermediate/low risk groups was 1.72 times higher in cases compared to controls (95% CI: 0.77 to 3.80; p = 0.181), but these differences were not significant. Conclusions: Our case-control study did not show a statistically higher RS for BC that develops in pts with g CHEK2 PV. Further studies are warranted to evaluate the association between type of CHEK2 PV (frameshift versus missense) and other modifying genetic variables and RS.

scholarly journals Epidemiology of Peripheral Lymph Node Tuberculosis and Genotyping of M. tuberculosis Strains: A Case-Control Study

PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132400 ◽  
Author(s):  
Chinmay Khandkar ◽  
Zinta Harrington ◽  
Peter J. Jelfs ◽  
Vitali Sintchenko ◽  
Claudia C. Dobler
Keyword(s):  
Lymph Node ◽  
Case Control Study ◽  
Case Control ◽  
Peripheral Lymph Node ◽  
Peripheral Lymph ◽  
Lymph Node Tuberculosis ◽  
Control Study

319. Minimally invasive surgery for neuromuscular scoliosis: a case control study of 140 consecutive patients

2019 ◽  
Vol 19 (9) ◽  
pp. S155
Author(s):  
Vishal Sarwahi ◽  
Jesse M. Galina ◽  
Romain Dayer ◽  
Sayyida S. Hasan ◽  
Aaron M. Atlas ◽  
...  
Keyword(s):  
Minimally Invasive Surgery ◽  
Minimally Invasive ◽  
Invasive Surgery ◽  
Case Control Study ◽  
Case Control ◽  
Neuromuscular Scoliosis ◽  
Control Study

scholarly journals Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

2015 ◽  
Vol 54 (4) ◽  
pp. 543-549 ◽  
Author(s):  
Claudia Lundgren ◽  
Cecilia Ahlin ◽  
Lars Holmberg ◽  
Rose-Marie Amini ◽  
Marie-Louise Fjällskog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Prognostic Marker ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Node Negative ◽  
Cyclin E1 ◽  
Node Negative Breast Cancer ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document